Marvin Slosman Biography and Net Worth

CEO of InspireMD

Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commercialization and international market development in both public and privately held companies. Prior to joining InspireMD, he served as a Business Consultant for Integra LifeSciences overseeing commercial strategy and market development for Integra’s international business. Before that, he served as President of ITAMAR Medical, a developer of cardiovascular and sleep diagnostic technologies. Prior to ITAMAR, Mr. Slosman served as Chief Executive Officer of Ovalum Vascular, Ltd., a privately held medical device company focused on vascular device innovations. Earlier in his career, Mr. Slosman served as Chief Executive Officer of Phormax Medical, Inc., Senior Executive Vice President and Chief Commercial Officer at Emerge Interactive in addition to senior commercial leadership positions at Johnson & Johnson, GE Healthcare and Baxter.

Mr. Slosman received a BS from The University of Alabama and an MBA from The University of Chicago.

What is Marvin Slosman's net worth?: The estimated net worth of Marvin Slosman is at least $2.43 million as of May 12th, 2026. Mr. Slosman owns 3,556,658 shares of InspireMD stock worth more than $2,429,197 as of September 29th. This net worth estimate does not reflect any other investments that Mr. Slosman may own. Learn More about Marvin Slosman's net worth.
How do I contact Marvin Slosman?: The corporate mailing address for Mr. Slosman and other InspireMD executives is 6303 Waterford District Drive, Suite 215, Miami, FL, 33126. InspireMD can also be reached via phone at 9728887766804 and via email at [email protected]. Learn More on Marvin Slosman's contact information.
Has Marvin Slosman been buying or selling shares of InspireMD?: Marvin Slosman has not been actively trading shares of InspireMD during the last ninety days. Most recently, on Tuesday, May 12th, Marvin Slosman bought 21,000 shares of InspireMD stock. The stock was acquired at an average cost of $1.20 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer now directly owns 3,556,658 shares of the company's stock, valued at $4,267,989.60. Learn More on Marvin Slosman's trading history.
Who are InspireMD's active insiders?: InspireMD's insider roster includes Gary Roubin (Director), Marvin Slosman (CEO), Paul Stuka (Director), and Scott Ward (Director). Learn More on InspireMD's active insiders.
Are insiders buying or selling shares of InspireMD?: In the last year, InspireMD insiders bought shares 9 times. They purchased a total of 303,771 shares worth more than $348,697.40. In the last year, insiders at the sold shares 12 times. They sold a total of 86,913 shares worth more than $126,870.28. The most recent insider tranaction occured on May, 27th when Director Paul Stuka bought 20,000 shares worth more than $17,600.00. Insiders at InspireMD own 25.0% of the company. Learn More about insider trades at InspireMD.
Information on this page was last updated on 5/27/2026.

Marvin Slosman Insider Trading History at InspireMD

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/12/2026	Buy	21,000	$1.20	$25,200.00	3,556,658
7/30/2025	Buy	10,330	$2.42	$24,998.60	2,420,866

Marvin Slosman Buying and Selling Activity at InspireMD

InspireMD Company Overview

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Today's Range

Now: $0.68

$0.68

$0.70

50 Day Range

MA: $0.79

$0.65

$0.98

2 Week Range

Now: $0.68

$0.63

$2.57

Volume

9,267 shs

Average Volume

140,532 shs

Market Capitalization

$31.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83